CME (CME Group) Research & Development: $0 Mil (TTM As of Mar. 2026)


CME CME Group Inc CME
81 GF Score
Price $231.58
GF Value $270.89
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is CME Group Research & Development?

CME Group CME -4.41% 81 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates CME with a GF Score™ of 81/100 and a GF Value™ of $270.89 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CME Group's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

CME Group  (NAS:CME) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CME Group Research & Development Related Terms

CME Group Research & Development Historical Data

* Premium members only.

The historical data trend for CME Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CME Group Research & Development Chart

CME Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CME Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CME
81GF Score
CME Group Inc CME
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CME Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
CME Group (CME) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CME Group and its competitors.
Is CME Group's Research & Development too high?
CME Group's current Research & Development is $0 Mil. Overall, CME Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CME Group's Research & Development compare to ICE and MCO?
CME Group's Research & Development of $0 Mil can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Capital Markets company?
A good Research & Development depends on the Capital Markets industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CME Group and its competitors. CME Group's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Modestly Undervalued. The stock's GF Value™ is $270.89, compared to a current price of $231.58 — trading 14.5% below its estimated fair value. The current Research & Development is $0 Mil. CME Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CME Group (CME), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CME Group (CME) Overvalued in 2026?

Based on GuruFocus' analysis, CME Group stock appears to be undervalued. The current stock price of $231.58 is trading 14.5% below its estimated GF Value™ of $270.89. GuruFocus considers CME Group to be Modestly Undervalued.

Key valuation signals for CME:

  • Research & Development: $0 Mil
  • GF Value™: $270.89 vs. price of $231.58 (14.5% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CME Group Business Description

Address 20 South Wacker Drive, Chicago, IL, USA, 60606
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
81GF Score

Get the complete analysis for CME

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$231.58
Price
$270.89
GF Value